Table 3.

Risk of breast cancer recurrence and mortality associated with PET uptake measures

 DFS
Univariate analysisMultivariate adjusted analysisa
CharacteristicNo. at riskNo. of recurrencesHR95% CIPbHR95% CIPb
Baseline K1c75180.630.32–1.230.180.190.06–0.610.003
Baseline Kic75181.070.70–1.630.761.130.61–2.100.70
Baseline SUVd75180.910.49–1.700.770.920.41–2.070.84
Mid-therapy K1c75181.490.96–2.320.071.550.79–3.040.19
Mid-therapy Kic75181.371.06–1.770.011.360.97–1.900.05
Mid-therapy SUVd75181.520.91–2.540.141.450.72–2.910.31
Change in K1e75181.161.07–1.270.0011.371.16–1.62<.0001
Change in Kie75181.201.05–1.370.011.200.99–1.440.06
Change in SUVe75181.220.97–1.530.081.190.90–1.570.21
OS
Univariate analysisMultivariate adjusted analysisa
Characteristic No. at risk No. of recurrences HR 95% CI P valueb HR 95% CI P valueb
Baseline K1c75180.860.38–1.960.730.270.06–1.210.07
Baseline Kic75181.130.68–1.870.641.310.59–2.910.50
Baseline SUVd75181.110.55–2.230.781.300.49–3.490.50
Mid-therapy K1c75181.580.94–2.660.081.880.85–4.160.11
Mid-therapy Kic75181.441.06–1.950.011.430.98–2.070.04
Mid-therapy SUVd75181.961.14–3.340.031.880.87–4.060.12
Change in K1e75181.161.05–1.280.0051.331.12–1.580.0003
Change in Kie75181.261.08–1.470.0061.210.98–1.490.07
Change in SUVe75181.381.04–1.840.021.270.91–1.780.16

aMultivariate adjusted HRs adjusted for ER, PR, tumor size (0–1.9, 2–5, and >5 cm), histology (ductal/lobular), pCR (pCR vs. other than pCR), and ALN positivity (0, 1–3, 4, or more).

bLikelihood ratio test.

cLog base 2, mL/min/g × 10−3.

dLog base 2.

e1 unit = 10 percent change.